## FORM 4

obligations may continue. See

Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Occident 10. Form 4 of Form 5		

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  TURKEL CATHERINE C.														all app Dired Offic	olicable) ctor er (give title	10% (	10% Owner Other (specify		
(Last) (First) (Middle) C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550				05/	3. Date of Earliest Transaction (Month/Day/Year) 05/20/2019									X below) below)  President					
				_   4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	,					
	Tabl	e I - N	on-Deriv	/ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefic	ially	Owne	ed				
I may be decountly (mean b)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)						nd 5) Secu Bene Owne		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) or (D)	Price		Trans	action(s)		(Instr. 4)			
Common Stock 05/20/20			2019	019		S <sup>(1)</sup>		7,623	D	\$1.9	616(2)	90,576		D					
mon Stock 05/21/2			2019	019		S <sup>(1)</sup>		1,914	D	\$1.9	\$1.9114 <sup>(3)</sup>		88,662						
	Та	ble II												vned					
Derivative Conversion Security Or Exercise (Month/Day/Year) Execution if any		ion Date,		ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			Amoun		Deri Seci (Inst	erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
	(Fin VUS THER ACARTHU  CA  (State of the Cartesian of the	CA Stock  Stock  2. Conversion or Exercise Price of Derivative Set CATHERINE C.  (First) (CATHERINE C.  (First) (CATHERINE C.  (State) (C	(First) (Middle) VUS THERAPEUTICS, INC. ACARTHUR BLVD., SUITE 550  CA 92612  (State) (Zip)  Table I - N  Security (Instr. 3)  Stock  Stock  Table II  2. Conversion or Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year)  Table II	(First) (Middle)  VUS THERAPEUTICS, INC.  ACARTHUR BLVD., SUITE 550  CA 92612  (State) (Zip)  Table I - Non-Deriv  Security (Instr. 3) 2. Transact Date (Month/Date (Month/Date))  Stock 05/20/2  Table II - Derivative (e.g., p  2. (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)	(First) (Middle)  VUS THERAPEUTICS, INC.  ACARTHUR BLVD., SUITE 550  CA 92612  (State) (Zip)  Table I - Non-Derivative  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Stock  05/20/2019  Table II - Derivative S (e.g., puts, comprise of Price of Poerivative (Month/Day/Year)  2. Conversion or Exercise Price of Price of Poerivative (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  2. (Conversion of Execution Date, if any (Month/Day/Year)  (Month/Day/Year)	Novus   Novu	Novus There   Novus There	Novus Therapeu	Novus Therapeutics,	Novus Therapeutics, Inc.	CATHERINE C.   Size   Catherine   Cather	Novus Therapeutics, Inc.   Novus Therapeutics,	Novus Therapeutics, Inc.   NVUS	Novus Therapeutics, Inc.   Novus Therapeutics, Inc.	Novus Therapeutics, Inc.   Novus   Novus Therapeutics, Inc.   Novus   Novus	Novus Therapeutics, Inc.   Novus Therapeutics, Inc.   Novus Therapeutics, Inc.   Novus Therapeutics, Inc.	Novus Therapeutics, Inc.   Novus Therapeutics, Inc.   Novus Therapeutics, Inc.   Novus Therapeutics, Inc.		

## **Explanation of Responses:**

- 1. Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units.
- 2. This transaction was executed in multiple trades at prices ranging from \$1.90 to \$2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from \$1.90 to \$1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

## Remarks:

/s/ Ryan A. Murr, as attorneyin-fact for Catherine C. Turkel

05/22/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.